159 related articles for article (PubMed ID: 16045292)
21. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
22. Comparison of metabolic soft spot predictions of CYP3A4, CYP2C9 and CYP2D6 substrates using MetaSite and StarDrop.
Shin YG; Le H; Khojasteh C; Hop CE
Comb Chem High Throughput Screen; 2011 Nov; 14(9):811-23. PubMed ID: 21605066
[TBL] [Abstract][Full Text] [Related]
23. Identification of cytochrome P450 2D6 and 2C9 substrates and inhibitors by QSAR analysis.
Jónsdóttir SÓ; Ringsted T; Nikolov NG; Dybdahl M; Wedebye EB; Niemelä JR
Bioorg Med Chem; 2012 Mar; 20(6):2042-53. PubMed ID: 22364953
[TBL] [Abstract][Full Text] [Related]
24. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
25. Polysaccharide peptides from Coriolus versicolor competitively inhibit model cytochrome P450 enzyme probe substrates metabolism in human liver microsomes.
Yeung JH; Or PM
Phytomedicine; 2012 Mar; 19(5):457-63. PubMed ID: 22305191
[TBL] [Abstract][Full Text] [Related]
26. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of the essential oil of chamomile (Matricaria recutita L.) and its major constituents on human cytochrome P450 enzymes.
Ganzera M; Schneider P; Stuppner H
Life Sci; 2006 Jan; 78(8):856-61. PubMed ID: 16137701
[TBL] [Abstract][Full Text] [Related]
28. Development of CYP3A4 inhibition models: comparisons of machine-learning techniques and molecular descriptors.
Arimoto R; Prasad MA; Gifford EM
J Biomol Screen; 2005 Apr; 10(3):197-205. PubMed ID: 15809315
[TBL] [Abstract][Full Text] [Related]
29. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.
Barecki ME; Casciano CN; Johnson WW; Clement RP
Drug Metab Dispos; 2001 Sep; 29(9):1173-5. PubMed ID: 11502723
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of recombinant cytochrome P450 isoforms 2D6 and 2C9 by diverse drug-like molecules.
McMasters DR; Torres RA; Crathern SJ; Dooney DL; Nachbar RB; Sheridan RP; Korzekwa KR
J Med Chem; 2007 Jul; 50(14):3205-13. PubMed ID: 17559204
[TBL] [Abstract][Full Text] [Related]
31. Principal component analysis of CYP2C9 and CYP3A4 probe substrate/inhibitor panels.
Nath A; Atkins W
Drug Metab Dispos; 2008 Nov; 36(11):2151-5. PubMed ID: 18566039
[TBL] [Abstract][Full Text] [Related]
32. Application of support vector machines to in silico prediction of cytochrome p450 enzyme substrates and inhibitors.
Yap CW; Xue Y; Li ZR; Chen YZ
Curr Top Med Chem; 2006; 6(15):1593-607. PubMed ID: 16918471
[TBL] [Abstract][Full Text] [Related]
33. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes.
Berry LM; Zhao Z
Drug Metab Lett; 2008 Jan; 2(1):51-9. PubMed ID: 19356071
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities.
Kosugi Y; Hirabayashi H; Igari T; Fujioka Y; Hara Y; Okuda T; Moriwaki T
Xenobiotica; 2012 Feb; 42(2):127-38. PubMed ID: 22117526
[TBL] [Abstract][Full Text] [Related]
35. Reconstitution of recombinant cytochrome P450 2C10(2C9) and comparison with cytochrome P450 3A4 and other forms: effects of cytochrome P450-P450 and cytochrome P450-b5 interactions.
Yamazaki H; Gillam EM; Dong MS; Johnson WW; Guengerich FP; Shimada T
Arch Biochem Biophys; 1997 Jun; 342(2):329-37. PubMed ID: 9186495
[TBL] [Abstract][Full Text] [Related]
36. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes.
Qi XY; Liang SC; Ge GB; Liu Y; Dong PP; Zhang JW; Wang AX; Hou J; Zhu LL; Yang L; Tu CX
Food Chem Toxicol; 2013 Jun; 56():392-7. PubMed ID: 23500771
[TBL] [Abstract][Full Text] [Related]
38. Development of Robust Quantitative Structure-Activity Relationship Models for CYP2C9, CYP2D6, and CYP3A4 Catalysis and Inhibition.
Gonzalez E; Jain S; Shah P; Torimoto-Katori N; Zakharov A; Nguyễn ÐT; Sakamuru S; Huang R; Xia M; Obach RS; Hop CECA; Simeonov A; Xu X
Drug Metab Dispos; 2021 Sep; 49(9):822-832. PubMed ID: 34183376
[TBL] [Abstract][Full Text] [Related]
39. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
Usmani KA; Karoly ED; Hodgson E; Rose RL
Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
[TBL] [Abstract][Full Text] [Related]
40. In vitro effects of active constituents and extracts of Orthosiphon stamineus on the activities of three major human cDNA-expressed cytochrome P450 enzymes.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
Chem Biol Interact; 2011 Mar; 190(1):1-8. PubMed ID: 21276781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
